UNITY Biotechnology Inc
Change company Symbol lookup
Select an option...
UBX UNITY Biotechnology Inc
FICO Fair Isaac Corp
CBDL Cbd Life Sciences Inc
HKXCY Hong Kong Exchanges and Clearing Ltd
TOMZ TOMI Environmental Solutions Inc
GDXD MicroSectors? Gold Miners -3X Inverse Leveraged ETNs
CWK Cushman & Wakefield PLC
NAUT Nautilus Biotechnology Inc
ZSANQ Zosano Pharma Corp
CHX ChampionX Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Unity Biotechnology, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The Company is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The Company's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.

Closing Price
$0.8501
Day's Change
-0.1199 (-12.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.02
Day's Low
0.85
Volume
(Heavy Day)
Volume:
641,046

10-day average volume:
527,599
641,046

Display:

Providers:

UpdateCancel
6 providers
Today's News, August 11, 2022
UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325 on Friday, August 12, 2022 at...(Globe Newswire)

July 12, 2022
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

EQNX::TICKER_START (NASDAQ:UBX), EQNX::TICKER_END UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from...(Globe Newswire)

June 29, 2022
UNITY Biotechnology Reports Granting of New Employment Inducement Award

EQNX::TICKER_START (NASDAQ:UBX), EQNX::TICKER_END UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from June 14, 2022, through June...(Globe Newswire)

May 26, 2022
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

EQNX::TICKER_START (NASDAQ:UBX), EQNX::TICKER_END UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current chief...(Globe Newswire)

May 25, 2022
UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference

EQNX::TICKER_START (NASDAQ:UBX), EQNX::TICKER_END UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.